Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Probe Gold Inc
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
F-star Therapeutics, Inc. - Common Stock
(NQ:
FSTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about F-star Therapeutics, Inc. - Common Stock
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
March 08, 2023
From
invoX Pharma
Via
Business Wire
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 07, 2023
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer
From
F-star Therapeutics, Inc.
Via
GlobeNewswire
invoX Pharma and F-star Therapeutics issue Joint Statement
January 26, 2023
From
F-star Therapeutics, Inc.
Via
GlobeNewswire
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
December 06, 2022
FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumors
From
F-star Therapeutics, Inc.
Via
GlobeNewswire
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
November 07, 2022
From
F-star Therapeutics, Inc.
Via
GlobeNewswire
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
July 15, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
FSTX STOCK ALERT: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
July 14, 2022
From
Halper Sadeh LLP
Via
Business Wire
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
June 23, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
FSTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
June 23, 2022
From
Halper Sadeh LLP
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1